Antipsychotic drug effects on motor activation measured by functional magnetic resonance imaging in schizophrenic patients.
Brain function and laterality in schizophrenia were investigated by means of a simple motor task with a self-generated left-hand sequential finger opposition (SFO) using a whole-brain high-speed (100 ms per slice) functional imaging technique. Neuroleptic-naïve, acutely ill schizophrenic patients were compared to schizophrenic patients under stable neuroleptic medication and matched controls. The goal was to evaluate both the motor function in first-episode patients and possible effects of different neuroleptic treatments on functional MRI results. Forty patients satisfying ICD 10 criteria (F20.x) for schizophrenia and sex- and age-matched healthy volunteers participated in this study. All subjects underwent fMRI examinations on a conventional 1.5 T MR unit. The primary sensorimotor cortex and the high-order supplementary motor area (SMA) were evaluated. There was a close similarity in the activation of the primary and high-order (SMA) sensorimotor areas between first-episode schizophrenic patients and controls. In contrast, a significant reduction in the overall blood oxygen level dependent (BOLD) response was seen in sensorimotor cortices (contra- and ipsilateral) in schizophrenic patients under stable medication with typical neuroleptics. This effect was not present in patients treated with atypical antipsychotics. Both antipsychotic treatments, however, led to a significant reduction in activation of the SMA region compared to controls and neuroleptic-naïve subjects. Thus, the present study provides no evidence for the localized involvement of the primary motor cortex or the SMA as a relatively stable vulnerability marker in schizophrenia. There is, however, strong evidence that neuroleptics themselves influence fMRI activation patterns and that there are major differences between typical neuroleptics and atypical antipsychotics.
Braus
D F
DF
Central Institute of Mental Health (ZI), NMR-Research, Mannheim, Germany. dfbraus@as200.zi-mannheim.de
Ende
G
G
Weber-Fahr
W
W
Sartorius
A
A
Krier
A
A
Hubrich-Ungureanu
P
P
Ruf
M
M
Stuck
S
S
Henn
F A
FA
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003024:Clozapine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009044:Motor Cortex / Q000033:anatomy & histology* / Q000187:drug effects* / Q000503:physiopathology; D010100:Oxygen / Q000097:blood; D011597:Psychomotor Performance / Q000187:drug effects*; D018967:Risperidone / Q000009:adverse effects*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D013003:Somatosensory Cortex / Q000033:anatomy & histology* / Q000187:drug effects* / Q000503:physiopathology
D014150:Antipsychotic Agents; D003024:Clozapine; D018967:Risperidone; D010100:Oxygen